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ABSTRACT
Influenza poses a threat to human health and is a burden on the global

economy. Influenza is caused by the influenza virus which contains a

segmented RNA genome, resulting in rapid evolution and emergence of new

influenza subtypes which may lead to pandemics. Defining molecular
interactions required for infection may reveal new antiviral targets to combat

emerging influenza threats. The most effective antiviral drug to provide treatment
against emerging influenza would be one that targets accessible, conserved
regions of influenza proteins that do not undergo antigenic variation but are

essential to the viral life cycle. Nucleoprotein (NP) is one such viral protein. NP
is highly conserved among influenza A subtypes and is a multifunctional viral

protein essential for viral gene expression.
NP is involved in the switch from viral transcription to viral genome

replication and three models have been proposed to demonstrate NPs
involvement in the switch. Two models involve NP interaction with viral RNA,

while the third model attributes the switch to NP interaction with viral RNA
dependent RNA polymerase (RdRP). In addition, NP has been proposed to

interact with host mRNA splicing and nuclear export factor UAP56. The NPUAP56 interaction is speculated to enhance viral RNA replication

One goal of this research was to investigate the NP-RdRP interaction by

identifying and characterizing a NP mutant which maintains RNA binding but is
unable to interact with the viral polymerase complex. We identified NPbd3 and
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initial characterization reveals this NP mutant interacts with nucleic acids, yet is
non-functional for viral gene expression.

A second goal of this research was to investigate the proposed NP-UAP56

interaction by constructing and characterizing an N-terminal deletion mutant,

del20NLS-NP. This NP mutant also maintains RNA binding but was defective for

viral gene expression with every gene template except NS. We hypothesized

that minimal expression of NS proteins resulted in the rescue of the RNA
expression defect observed in the presence of del20NLS-NP. Adding back

NS1A protein resulted in rescue of the de!20NLS-NP gene expression defect,
suggesting a functional interaction between NP and NS1A.

A detailed understanding of the mechanism in which NP interacts with

other viral proteins, such as NS1A and the RdRP, and with host factors such as
UAP56 can reveal promising antiviral targets. This work demonstrates the

importance of NP and NP interactions for viral RNA and gene expression.
Understanding how the virus transitions through its life cycle may illuminate

exploitable points that can be targeted to combat this pathogen. Disrupting these
essential NP interactions would disrupt viral RNA synthesis. This work supports
the notion that NP could be explored as a potential antiviral target to fight

seasonal flu infections and have an effective weapon during times of severe
epidemic or pandemics.

ACKNOWLEDGMENTS

I would not have been able to complete this milestone in my life without
the love and support of my wife and daughter. Your sacrifice, patience, and

understanding during this chaotic journey reminds me how blessed 1 am to have

both of you by my side. I also want to thank my parents for all their hard work as

I was growing up which created opportunities for me to get an education. I hope

this work demonstrates to my entire family that I have not taken for granted their
sacrifices and hard work.

I want to thank Laura Newcomb for extending me the opportunity to work
in her lab. I will always be proud to be a member of the Newcomb Lab. I want to

express my gratitude to the other members of my Thesis Committee, Michael

Chao and Paul Orwin, for their guidance and help in completing my project. I
want to acknowledge the Biology Department for providing me an opportunity for

a well rounded graduate education.
Finally I want to express my appreciation to Moreno Valley College for

extending me the flexibility to obtain my Master’s Degree. More specifically, I

want to thank Steve Wagner for his encouragement. Even though disguised in
sarcasm, I want to thank you for your support.

TABLE OF CONTENTS

ABSTRACT

..........

iii

............................................................................................

AKNOWLEDGMENTS

LIST OF FIGURES

v

ix

........

CHAPTER ONE: SIGNIFICANCE AND BACKGROUND

Introduction

1

.......................................................

Viral Life Cycle

3

.....

Antigenic Variation

6

....................

Vaccination and Antiviral Drugs Against the Influenza Virus

Nucleoprotein as a Target for Antiviral Drugs

Nucleoprotein is a Multifunctional Protein

................

8

........................................

10

..............................................

11

CHAPTER TWO: METHODS AND MATERIALS
Cell Lines

.............................................
.................................................................................

18

................................................................................................

19

Plasmid Construction
Transfection

18

Recombinant Viral Ribonucleoprotein Assay

20

........

Protein/RNA Isolation

............................................................................... .

20

Total Protein Isolation

...............................................................................

20

Total RNA Isolation

.................................

Cytoplasmic and Nuclear Protein and RNA Isolation

Reverse Transcription Polymerase Chain Reaction
Dual Crosslinking

....................................

vi

20

.......

21

.............................
...........

21

22

Co-lmmunoprecipitation ....................................................

23

SDS-PAGE and Western Analysis

23

Antibodies

..........................................................

24

......................................................................

GFP Detection

24

.....................................................................

Binding and Oligomerization Assays

.................

24

CHAPTER THREE: NUCLEOPROTEIN AND POLYMERASE COMPLEX
INTERACTIONS

Introduction

........................ ........................................................................

Amino Acid Modifications to Nucleoprotein
NPbd3 and NPbd5 Function

............................................

27
28

........................

NPbd3 RNA Binding and Oligomerization

26

..............................................

29

NPbd3 Interaction with the Polymerase Complex .................................

29

Summary

30

.......

CHAPTER FOUR: N-TERM1NAL NUCLEOPROTEIN INTERACTIONS

Introduction .................................................................................................

38

Construction of del20NLS-NP ....................................

39

del20NLS-NP is Expressed in the Nucleus
the Same as Wild Type NP ......................................................................

39

del20NLS-NP Retains Nucleic Acid Binding as Wild Type NP

...........

40

Activity of de!20NLS-NP with NS and M vRNA Templates

...........

41

.........

43

...............

44

NS1 Protein Rescues the RNA Expression Defect
Observed with del20NLS-NP ...................................................................

45

del20NLS-NP is Defective for Both Early and Late Viral Genes
del20NLS-NP is Defective for Short Viral Gene Expression

vii

Summary

46

...........................................

CHAPTER FIVE: DISCUSSION AND FUTURE RESEARCH

Introduction

.................................................................................................

Nucleoprotein andPolymerase Complex Interaction

58

.............................

58

Nucleoprotein N-Terminal Interactions ....................................................

61

Conclusion

................................................................................................... 66

REFERENCES CITED

...................................................................

viii

69

LIST OF FIGURES
Figure 1.

Influenza virion structure...................................................................

14

Figure 2.

Nucleoprotein three dimensional structure.....................................

15

Figure 3.

Viral ribonucleoprotein complex.......................................................

16

Figure 4.

Proposed nucleoprotein interactions............................

17

Figure 5.

Expression of recombinant viral
ribonucleoprotein complexes............................................................

25

Figure 6.

Three dimensional model of nucleoprotein monomer...................

31

Figure 7.

Wild type NP-FLAG is as functional as untagged
wild type NP..........................

32

Figure 8.

293T expression and function of NPbd3 and NPbd5....................

33

Figure 9.

Analysis of NPbd3 and NPbd5 through
expression of GFP tagged proteins................................................

34

Confirmation of NPbd3 and NPbd5
function at the level of RNA............. ................................................

35

Figure 11.

NPbd3 binds nucleic acids as wild type NP. .................................

36

Figure 12.

Wild type NP-FLAG co-imunopurifies with PB1-GluGlu...............

37

Figure 13.

Deletion of N-terminus 20 amino acids of nucleoprotein..............

47

Figure 14.

Expression of del20NLS-NP in the nucleus
and the cytoplasm as wild type NP.................................................

48

Figure 15.

Nucleoprotein purification and nucleic acid binding......................

49

Figure 16.

Western blot analysis of tagged and
untagged NS and M genes............ ..................................................

50

Expression of M and NS genes tagged with GFP.........................

51

Figure 10.

Figure 17.

ix

Reverse transcription polymerase chain reaction
analysis to confirm defect in the presence of
de!20NLS NP is at the level of RNA expression...........................

52

Expression of PA and PB1 vRNA
templates with del20NLS-NP..........................................................

53

Figure 20.

Expression of HA vRNA with del20NLS-NP..................................

54

Figure 21.

Short M Gene expression was defective
with del20NLS-NP............................

55

Figure 22.

NS1 rescues expression defect with M template...........................

56

Figure 23.

NS1 rescues expression defect with PA template.........................

57

Figure 24.

RNA binding mutant, NS1R38A also
rescues the de!20NLS-NP defect...................................................

68

Figure 18.

Figure 19.

x

CHAPTER ONE
SIGNIFICANCE AND BACKGROUND

Introduction
Influenza is respiratory illness caused by the influenza virus that poses a

threat to human health and the global economy. Estimates reveal that 3 to 5
million people are infected by the influenza virus yearly, and of these infections

250,000 to 500,000 result in death (World Health Organization 2009). In the

United States an average of 150,000 individuals are hospitalized with influenza
infections or influenza related complications (Cox 2000) and an average of

41,000 people die each year (Dushoff 2006). This leads to an $87 billion burden
on the U.S. economy (Molinari 2007). The 20th century was witness to three

influenza pandemics (Cox 2000). In 2009 the Swine flu became the first
pandemic of the 21st century and early figures suggest the global monetary
impact to be at $3 trillion (Lagace 2010). This makes the search for an effective

treatment for influenza infection a priority.

The influenza virus belongs to the family Orthomyxoviridae and is
categorized into 3 types; A, B, and C. Influenza C is the least studied of the 3

types due to its low pathogenicity. Slight differences to the virion structure and
genome make type C unique compared to types A and B (Racaniello 1979).
Although influenza C has been shown to circulate worldwide, outbreaks have

been limited (Matsuzaki 2002). Influenza B is known to cause infection in
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humans and seals and the current circulating strains are included in the annual
influenza vaccines because of their potential to cause severe epidemics

(Osterhaus 2000). There have been no reported influenza B pandemics to date

(Hay 2001). Influenza type A is the most common circulating of the three types,
causing seasonal flu infections and sometimes pandemics. Similarities and
differences between the three influenza types will be highlighted but the focus of

this research will be on influenza A.
Influenza is an enveloped, negative sense RNA virus. Type A and B are
structurally similar and have a genome composed of 8 segments that encode for

at least 11 viral proteins (Bouvier 2008). Most segments result in one viral
mRNA encoding one viral protein. Two segments, M and NS, result in mRNA
that is spliced and encodes proteins from both the intron-containing mRNA and

the spliced mRNA. The influenza virion structure is composed of a host derived

membrane that contains 3 viral surface glycoproteins: HA, NA, and M2. The M1

protein forms a matrix immediately below the virion membrane completing the
virion envelope. The core of the virion is composed of nuclear export protein

(NEP/NS2) and the viral nucleoprotein complexes (vRNP). The influenza C

genome is composed of 7 segments that encode for at least 9 proteins where the
HEF protein serves the function of the HA and NA proteins in influenza A and B

(Bouvier 2008). Each of the 8 or 7 viral RNA segments are bound by the RNA
dependent RNA polymerase (RdRP) and coated with nucleoprotein (NP) forming
functional vRNPs (Du 2010) (Figure 1).
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Viral Life Cycle

An influenza virus infection is initiated when the virus attaches to a host

cell via HA interactions with host cell sialic acid residues that are ubiquitous in

human tracheal epithelial cells and in many other animal species. HA is a
surface glycoprotein that is a major receptor binding and membrane fusion
influenza structural protein (Skehel 2000). Once fused, the virion is endocytosed

and the M2 ion channel acidifies the endosome interior which facilitates the
release of the vRNPs into the host cell cytoplasm (Palese 2007). The
nonconventional nuclear localization signal (NLS) on the N-terminus of NP

directs the proper transport of vRNPs into the nucleus via host cell karyopherin
a/importin a, a protein involved in importing host cell proteins to the nucleus
(Cros 2005, Goldfarb 2004, Wang 1997). NP is a multifunctional protein that has

viral RNA binding activity (Portela 2002), is involved in the transport of vRNPs

into the nuclei (Cros 2005, Wang 1997), and is involved in viral RNA synthesis
(Biswas 1998, Klummp 1997, Mena 1999, Momose 2001, Newcomb 2009,

Ozawa 2007, Portela 2002, Vreeede 2004).
Once functional vRNPs reach the nucleus the RNA dependent RNA

Polymerase (RdRP) uses the negative sense vRNA as a template to make viral
mRNA. Viral mRNA is a shorter copy of the negative sense vRNA and is
transcribed in the nucleus, where it gets its 5’ cap via a “cap snatching

mechanism” (Krug 1989, Rao 2003) and is also polyadenylated (Li 1994, Zheng
1999). The RdRP is composed of 3 subunits: PB1, PB2, and PA. In the nucleus
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the PB2 subunit recognizes and binds to the 5’ cap of host cell mRNA transcripts

(Blaas 1982). The PA subunit, through its endonuclease activity, cleaves the 5’

cap resulting in 10-13 nucleotides (Dias 2009) used by the PB1 subunit as primer
to continue with RNA chain elongation (Palese 2007). RNA chain elongation
continues until the RdRP reaches a short stretch of uridines (U) residues where it
“stutters” to create the poly A tail on viral mRNA (Li 1994, Zheng 1999). The final

product is a 5’ capped and 3’ polyadenylated viral mRNA that appears similar to

host mRNA and can be exported out of the nucleus for protein synthesis.
Nuclear export of viral mRNA is accomplished by host cell export processes as a

result of its similarity to the host cell mRNA, although the exact mechanism of

influenza mRNA nuclear export remains undefined.

The negative sense influenza vRNA genome serves as both the template
for viral mRNA synthesis and complementary RNA (cRNA) synthesis. While viral

mRNA synthesis depends on a primer derived from host capped mRNA
fragments (Blaas 1982, Dias 2009, Krug 1989, Rao 2003), cRNA synthesis is

primer independent and generates a full length complementary copy ((+) cRNA)

of the negative sense vRNA template (Palese 2007). This occurs when the

polymerase complex reads through the stretch of U’s that give rise to the poly A
tail in viral mRNA. The product is an exact complement of the vRNA, termed
cRNA (Zheng 1999). The cRNA is then used to make more vRNA as templates

for transcription and as new viral genomes. The exact mechanism by which the

viral RdRP switches from mRNA transcription to cRNA replication is still unclear,
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but NP plays some role in the switch (Beaton 1986, Klummp 1997, Newcomb
2009, Vreede 2004).

There have been three models, which involve NP, proposed to result in

the switch from transcription to replication. The “stabilization” model
hypothesizes that when functional vRNPs enter the nucleus, 5’ capped and
polyadenylated viral mRNA as well as cRNA are produced simultaneously by the

RdRP. Since there are no free polymerase subunits or NP to bind nascent

cRNA, it is degraded by the host cell. Once viral proteins are synthesized in the
cytoplasm and imported into the nucleus, they bind nascent cRNA, protect it from

being degraded by the host cell, and proceed to viral genome replication (Veerde
2004). In this model NP functions to help stabilize incipient cRNA and protect it
from degradation. A second model, the “template modification” model, proposes

that free NP binds template RNA and modifies its structure. This interaction

could result in the interruption of the transcription process resulting in a shift to

template replication (Klumpp 1997). The third model, the “polymerase
modification” model, attributes the transition from transcription to replication as a
result of a direct interaction between NP and the RdRP (Newcomb 2009).
Once genome replication is complete in the nucleus the resulting 8 gene

segments are exported to the cytoplasm and are sorted and packaged forming a

new virion which buds from the cell membrane with the help of the
neuraminidase (NA). NA is a surface glycoprotein with sialidase activity that
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cleaves sialic acid so that newly synthesized virions are released from the host
and are ready to infect other cells (Bouvier 2008, Palese 2007).

Antigenic Variation

Many pathogens use antigenic variation as a method to evade the host
immune response, this involves altering their surface glycoproteins. The
influenza virus uses antigenic variation as one mechanism to evade host immune

responses. The result of HA and NA antigenic variation are 16 HA and 9 NA

subtypes identified to date. Only H1N1, H2N2, and H3N2 subtypes have been

associated with human epidemics (Cox 2000).

Antigenic variation in HA and NA

arises in one of two ways: antigenic drift or antigenic shift. The accumulation of

point mutations on HA and NA genes lead to antigenic drift. The high rate of
point mutations is due to the lack of proof reading ability by the RNA dependent

RNA polymerase (Palese 2007). If the point mutations are non-deleterious and
increase virus fitness, then they will be preserved and amplified. Antigenic drift

provides HA and NA proteins the ability to escape host cell neutralization (Cox
2000). Antigenic shift results when a circulating influenza virus has a new HA

variant, with or without a new NA variant, introduced into the human population.
This can happen when an animal or avian influenza virus is transmitted without

reassortment from an animal reservoir to humans or if there is genetic
reassortment between animal and human influenza A viruses that are circulating
(Cox 2000). The result of antigenic variation in HA and NA leaves individuals
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with immunity (natural immunity or vaccination) to previously circulating strains
susceptible to newly evolved strains. As newly evolved strains begin to circulate

in the human population they are selected for until they replace the previously
circulating strain. During this replacement period they co-circulate for a short
time until the old strain is completely replaced by the new strain.
Aquatic birds are the natural reservoir for the influenza virus although it

has been isolated from humans, pigs, horses, dogs, and domestic and wild birds.
Pigs have been identified as the mixing vessel for the different influenza strains

since they can be infected with both avian and human virus strains. Within pigs
genetic reassortment can occur and then transmit newly reassorted strains to

either birds or humans (Johansson 2007). Of great concern is the highly
pathogenic H5N1 influenza virus or avian flu. This subtype circulates primarily in
birds but H5N1 infections have occurred in humans. The main factor that limits

the avian flu host range is HA receptor specificity. HA of human influenza

viruses preferentially bind to sialic acids that are found in the upper respiratory
tract and those of avian viruses bind to sialic acids found in the lower respiratory

tract (Rogers 1983). Limited numbers of the primary receptors for the avian flu

can be found in mammalian upper respiratory tracts (Shinya 2006) and can be a

reason for low transmissibility of the avian flu from birds to humans or human to
human. Avian flu infection can occur through prolonged, close contact of
humans with infected birds or other infected humans (Gambotto 2008). Influenza

virus remains an emerging threat due to the high mutation rate and potential for
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segment reassortment, raising concern that a virulent influenza like H5N1 may
acquire the ability to rapidly transmit among humans.

Vaccination and Antiviral Drugs Against
the Influenza Virus

The most accepted method to control the influenza virus is through
vaccination to prevent infection. There are two types of vaccinations in use,
conventional inactive vaccine (CIV) and live attenuated vaccine (LAV). CIVs are

derived from inactive high yield reasortant viruses and administered as a
subcutaneous shot. LAVs are derived from a master donor virus strain with

temperature sensitive, cold adapted, and attenuated mutations in several of the

genes that code for internal influenza proteins (Cox 2000). Influenza vaccines
contain HA and NA proteins from the most recent influenza virus strains that are
predicted to circulated in the next flu season. As a result of HA and NA antigenic

variation, vaccine development depends on accurate predictions of future HA

and NA antigenic variants. Therefore, newly developed vaccines for upcoming

flu seasons are only effective if the HA and NA predicted variants are the same
as the circulating variant. This means seasonal vaccines provide immunity that
is short lived due to the rapid evolution of HA and NA and are likely ineffective

against a rapidly emerging virulent strain. The predicted influenza strains used to

create vaccines are cultured in eggs. Although this method is widely used, it

presents many obstacles, such as inefficient vaccine development during
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pandemics, long and complicated production cycles, and limited capacity (Cox
2000, Johansson 2007).
Antiviral medications treat individuals already infected and exploit the

influenza virus life cycle, specifically at the entry and exit steps of the virus life

cycle, targeting M2 and NA membrane proteins, respectively. Amantadine and
rimantadine target the M2 channel protein resulting in the virus losing its ability to
uncoat the virion and release the vRNPs for proper trafficking into the nucleus.

However, these antivirals are most efficient when administered early in viral
infection. Unfortunately, selective pressure put on the M2 channel protein results

in the rapid evolution of antiviral resistant mutants. Another drawback to these

M2 targeted antivirals is they are only effective when dealing with influenza A
viral infections and they do not work on influenza B viruses. Zanamivir and

oseltamivir are examples of NA inhibitors. Unlike amantadine and rimantadine,
these antiviral drugs work on both influenza A and B by blocking the function of

the NA protein resulting in no release of virion particles from infected cells.
Although these antivirals can be effective later in viral infection, they are also

affected by the rapid evolution of HA and NA proteins. NA mutants resistant to
neuraminidase inhibitors have been identified. HA mutants resistant to
neuraminidase inhibitors have also been identified. In this case HA mutants

have developed the ability to release the virion when the NA activity is inhibited
by neuraminidase inhibitors (Blaser 2007). A last example of an antiviral drug for
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influenza A and B is ribavirin, but this drug has toxicity and drug delivery issues
(Blaser 2007).
The main target of current vaccines and antivirals for influenza A and B
are HA and NA proteins. As previously mentioned, HEF replaces HA and NA in

influenza C, making previously mentioned approaches to control influenza
infections ineffective against an influenza C infection. To date there have been

no vaccines or antiviral drugs developed to control influenza C infections.

Nucleoprotein as a Target for Antiviral Drugs
The limiting factor in the development of an efficient influenza vaccine or

antiviral drug is circumventing the HA and NA antigenic variation characteristic of
the influenza virus. It has been suggested that the most effective vaccine or
antiviral drug is one that targets accessible, conserved regions of influenza

proteins that do not undergo antigenic variation (Blaser 2007, Du 2010,
Johansson 2007, Li 2009, Mena 1999, Portela 2002, Shu 1993). An excellent

candidate of such an influenza protein with conserved regions across all

influenza subtypes, with little antigenic variation, and which has multifunctional
characteristics throughout the influenza virus life cycle is the nucleoprotein (NP).

Previous work has shown that various isolated influenza strains of different
subtypes have several NP regions that are conserved. The mutation rate of NP
is low regardless of the antigenic variation of HA and NA proteins (Shu 1993).

Mutational analysis of conserved NP amino acids (Li 2009, Mena 1999), together
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with insight from the NP crystal structure (Ye 2006), has given support to the idea
that an effective novel influenza antiviral drug should target NP conserved
regions.

The influenza A, B, and C NP genome segments encode 498, 560, and

565 amino acid polypeptides, respectively. When the nucleotide sequence for

each of the influenza types is aligned, several sequence similarities are observed
across the three types and influenza A and B share the most similarities between

the three types. Overall analysis of NP across the air types shows there is only

an 11% difference in amino acid sequence (Shu 1993). The NP crystal structure
shows the NP protein oligomerizes specifically forming a trimer of about 150 kDa
in size. NP monomer structure consists of a head domain, body domain, and a

tail loop (Figure 2). The head domain is formed by amino acid residues 150 to

272 and 438 to 452. The body domain consists of the amino acid residues 21 to
149, 273 to 396, and 453 to 489. The tail loop is composed of amino acid
residues 402 to 428 and is critical for oligomerization and formation of a

functional nucleoprotein. The crystal structure shows a deep groove between the

head and body domains that consists of multiple positively charged amino acids,

such as arginine and lysine and comprises the RNA binding domain (Ye 2006).

Nucleoprotein is a Multifunctional Protein
Nucleoprotein is a multifunctional protein that interacts with both viral and

host proteins at various times during viral infection. NP interacts with both vRNA
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and the viral RdRP as a major component of transcriptionally competent viral
ribonucleoproteins (vRNPs). The interaction between NP and the RdRP is
reported to be directly with the PB1 and PB2 subunits of the RdRP complex, and
not with PA, the third subunit of the RdRP complex (Biswas 1998). A three

dimensional structural model of a mini recombinant vRNP shows the manner in
which NP, vRNA, and RdRP interact in vivo to form a functional vRNP (MartinBenito 2001, Nagata 2008) (Figure 3).

NP interactions with host cell proteins have also been identified. The host
cell protein karyopherin a/importin a functions primarily to transport NLS

containing proteins into the nucleus (Goldfarb 2004). Viral RNA synthesis occurs
in the nucleus of the host cell, and import of vRNPs is accomplished via an

unconventional NLS that is located between the amino acid 1 and 13 of NP (Cros

2003, Cros 2005) and contains the karyopherin a/importin a binding site (Wang

1997). Mutations in the N-terminus of NP result in an NP that cannot import
vRNPs into the nucleus, and as a consequence inhibits viral replication (Cros
2005, Digard 1999). The interaction between NP and CRM1, a member of the

importin |3 family involved in the transport of proteins across the nucleus in both

directions, is responsible for the nuclear export of vRNPs during virion assembly
(Elton 2001). The reported mechanism for retention of the vRNPs in the

cytoplasm during virion assembly is thought to be due to an interaction between
NP and filamentous actin (F-actin) (Digard 1999).

12

NP also interacts with host transcription elongation factor Tat-SF1 and
mRNA processing and nuclear export factor UAP56 (Nagata 2008). Tat-SF1
increases the processivity of RNA polymerase II (Parada 1999, Zhou 1996).
Host cell UAP56 is an important splicing factor that is not only involved in pre-

mRNA processing but also mRNA nuclear export (Linder 2001, Meignin 2008).
In this process UAP56 is involved in the formation of the pre-spliceosome and
recruits additional factors such as Aly, which in turn connect mature mRNA to the
Nxf1 nuclear export pathway (Shen 2009). In vitro analysis reported that Tat-

SF1 and UAP56 interact with unbound NP and not with NP bound to RNA,
suggesting that they act as molecular chaperones facilitating the formation of NP-

RNA complexes and consequently cause an increase in viral RNA synthesis

(Nagata 2008). GST pull down analysis has identified the first 20 amino acids of

NP as sufficient for UAP56 interaction (Momose 2001). Figure 4 illustrates

mapped NP interactions.
This thesis focuses on characterizing two NP mutant proteins in order to

better understand the role of NP during viral RNA synthesis and processing. NP
mutants were constructed to target and disrupt either the NP-RdRP or the NP-

UAP56 interactions. Two mutants resulted in defects in viral RNA synthesis.

Characterization of these NP mutants should result in a better understanding of
the interactions and role of NP during viral RNA synthesis and processing. This

may further lead to the identification of novel antiviral targets.
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lipid bilayer

---------- M2
b----------HA

of the composition of the influenza virion. The eight virion gene
segments result in at least 11 protein products. The PB1-F2

protein product which is encoded from an alternate reading frame
on the PB1 mRNA is not represented in this schematic.

Du L, Zhou Y, and Jiang S. 2010. Research and development of
universal influenza vaccines. Microb Infect, 12, 280-286.
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Figure 2. Nucleoprotein three dimensional structure. A three
dimensional representation of a nucleoprotein monomer showing
the head domain, RNA.binding domain, body domain, and tail loop.

Ye Q, Krug RM, and Tao YJ. 2006. The mechanism by which
influenza A virus nucleoprotein forms oligomers and binds RNA.
Nature, 444(21), 1078-1082.
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EMBO Reports, 2001,2(4), 313-317

B

Viral

Rev Med Virol., 2008, 18, 247-260

Figure 3. Viral ribonucleoprotein complex. (A) Electron micrograph of a

functional mini-vRNP. (B) Illustration of a functional vRNP showing how NP,
PB1, PB2, and PA interact with vRNA.
Martin-Benito J, Area E, Ortega J, Llorca O, Valpuesta JM, Carrascosa JL, and

Ortin J. 2001. Three-dimensional reconstruction of a recombinant influenza
virus ribonucleoprotein particle. EMBO reports, 2(4), 313-317.

Nagata K, Kawaguchi A, and Naito T. 2008. Host factors for replication and

transcription of the influenza virus genome. Rev Med Virol, 18, 247-260.
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Figure 4. Proposed nucleoprotein interactions. Mapped interactions of NP with

viral and cellular host factors.
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CHAPTER TWO
METHODS AND MATERIALS

Cell Lines
293T cells were purchased from ATCC with material transfer agreement

and maintained at 37°C with 5% CO2.

Plasmid Construction

pcDNA plasmids expressing Influenza A Udorn wild type proteins PA,
PB1, PB2, NP, NS1A, NS1R38Aand pHH21 plasmids expressing untagged M

and NS vRNA were gifts from the Krug laboratory. The pcDNA plasmid

expressing WT-NP containing a C-terminal FLAG epitope tag was constructed
using PCR (primers from Operon). The pcDNA plasmids expressing NPbd3 and

NPbd5 were constructed in a similar manner and added changes to NP at
residues 289, 293, 294, 308, and 309 (NPbd3) and 467, 469, 470, 471, and 472

(NPbdS) using PCR (primers from Operon). In addition to proper restriction
enzymes sites, the 5’ primer encoded the start codon and the first amino acids of
NP while the 3’ primer encoded the last amino acids of NP followed by a short

glycine linker and the FLAG epitope tag (DYKDDDDK) prior to the stop codon.

The del20NLS-NP was constructed in a similar manner using the same 3'primer
but in this case the 5’ primer encoded the conventional NLS from SV40 T antigen

(PKKKRKV) in between the start codon and NP codon 21. The PCR products
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were digested with EcoRI and Xbal and ligated into pcDNA. pHH21 FLAG-NS
vRNA, FLAG-M vRNA, FLAG-M short vRNA, GFP-M vRNA, and GFP-NS vRNA

were constructed by two step PCR. The first step resulted in two DNA
fragments, one encoding the 5’ UTR-start codon fusion tag and 5’ portion of the

viral gene, the second encoding an overlapping region of the 5’ portion of the
viral gene through the 3’ end. The two DNA fragments are used as templates in
the second PCR step with BsmB1 5’common UTR and BsmB1 3’common UTR

primers to produce the entire fusion coding sequence. The DNA insert was

digested with BsmB1 and inserted into pHH21. All newly constructed plasmids

were sequenced confirmed'at the CSUPERB Sequencing Facility at San Diego

State University.

Transfection
293T cells were grown to approximately 70% confluency in either 10cm or

6-well plates depending on the experiment. Plasmid DNA was purified using

Qiagen QIAprep spin plasmid purification kits per manufacturer’s protocol. DNA

with pcDNA plasmids PB1, PB2, PA, and either WT-NP, NPbd3, NPbd5,
de!20NLS NP, vector, NS, NS1A, or NS138A along with the appropriate pHH21

plasmid to express the vRNA template was mixed with Mirus transfection reagent

at 1:3 ratio of DNA to reagent as per manufacturer’s protocol. 48 hours post
transfection cells were washed with 1X PBS and collected by centrifugation.
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Recombinant Viral Ribonucleoprotein Assay

NP, PB1, PB2, PA, NS, and NS1A were expressed from pcDNA vectors
which have a transcription promoter for RNA polymerase II. The vRNA
templates were expressed from pHH21 plasmids which have a transcription

promoter RNA polymerase I. See Figure 5.

Protein/RNA Isolation

Total Protein Isolation
Cell pellets were resuspended in 10 volumes of the cell pellet of RIPA

(Lysis) Buffer (25mM HOI pH 7.6, 150mM NaCI, 1% deoxycholate, 0.1% SDS)

with protease inhibitors. Cells were lysed using Fisher Scientific Sonic
Dismembratorfor 10 pulses at 30%, output 3-4. Sonicated materials were

centrifuged at 1500xg for 15 minutes at 4°C to clarify total cell extract.

Total RNA Isolation

Total RNA was isolated from 6-weel dishes using Trizol (Invitrogen)

according to manufacturer’s protocol. RNA was quantified and evaluated for
purity by taking OD260 and OD280 readings on the NanoDrop ND1000

Nanospectrophotometer.
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Cytoplasmic and Nuclear Protein and RNA Isolation
Cell pellets were washed twice at 5 volumes of the cell pellet in

Reticulocyte Standard Buffer (RSB: 10mM Tris HCI pH7.5, 10mM KCI, 1.5mM
MgCfe) with protease inhibitors. Cells were then resuspended in RSB at 10X the
volume of the cell pellet and incubated on ice for 10 minutes. NP-40 was added

at a final concentration of 0.2% to disrupt plasma membranes. Visual inspection
of the cells before and after addition of NP-40 ensured burst plasma membranes

and intact nuclei. Nuclei were pelleted by centrifugation at 300xg for 8 minutes at
4°C. The cytoplasmic extract was collected and the nuclear pellet was

resuspended in Dignam Buffer C without glycerol (20mM HEPES pH 7.9, 0.42M
NaCI, 1.5mM MgCfe, 0.2mM EDTA), plus protease inhibitors, to release nuclear
molecules. Both nuclear and cytoplasmic extracts were clarified from debris by

high speed centrifugation for 10 minutes at 4°C. An equal amount of 20mM

HEPES pH 7.9, 0.2mM EDTA was added to the nuclear extract to reduce the
total NaCI and MgCk concentrations.

Reverse Transcription Polymerase Chain Reaction

RNA was first treated with RNase-free DNase (Promega) to degrade any
contaminating plasmid DNA. 1 pg cytoplasmic or total RNA was subject to

reverse transcription using Promega reverse transcription system per
manufacturer’s protocol with oligo dT as primer; however reverse transcription
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time was increased to 60 minutes to facilitate complete first strand cDNA
synthesis. Primers used in PCR are as follows:

FLAG-M detection: (5'UTR Flag) GGTACTGATTCGAGATGGACTACAACC,
(3'M2 at nucleotide 833) CGATCAAGAATCCAC, GFP-M detection: (5'UTR
GFP) GCAAAAGCAGGTAGATATTGAAAGATGGTGAGCAAGGGC, (3'M2 at

nucleotide 833) CGATCAAGAATCCAC, FLAG-NS and GFP-NS detection:
(5'NS1/NS2 at nucleotide 29) GGATTCCAACACTGTG, (3'NS2 at nucleotide

718) GCCATCTTATCTCTTCG.

PCR products were separated on 1 % agarose gels. Gels were analyzed
with the UV setting on the ChemiDoc™ XRS (BioRad) system and digital images
were captured using Quantity One software.

Dual Crosslinking
48 hours post transfection, 10mM DMA in 1X PBS, was added directly to

each plate and incubated for 15 minutes at room temperature. DMA crosslinking
was quenched by incubating with 1mL DMA quenching buffer pH 8.0 (1X PBS,

100 mM Tris-HCl, 150 mM NaCI) for 5 minutes. Cells were washed once with 1X
PBS prior to second crosslinking incubation. Cells were incubated in 1%

formaldehyde for 10 minutes at 37° C. Formaldehyde crosslinking was quenched
by incubating in 125mM glycine for 5 minutes.
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Co-lmmunoprecipitation

Total protein extracts were incubated with a-FLAG antibody (Stratagene)
(1:50) and protease inhibitors for 1 hour at 4° C. Extracts were then incubated

with PA/G sepharose beads with protease inhibitors at 4° C overnight. The
samples were then spun for 1 minute at 1.0 x g at 4° C. Supernatant was
collected. Beads were resuspended in 0.00125mM 3X FLAG Peptide and
incubated overnight at 4° C. Samples were then centrifuged at 1.5 x g for 1

minute. Supernatant, containing purified proteins, was collected. Samples were
separated by SDS-PAGE. Western blot analysis was performed with appropriate

antibodies to detect FLAG tagged NP products, polymerase proteins, UAP56

protein, and Tat-SF1 protein.

SDS-PAGE and Western Analysis
Protein extracts were separated by SDS-10% PAGE. Proteins were
transferred to nitrocellulose using Fisher semi-dry blot apparatus and probed with

primary and HRP-conjugated secondary antibodies as indicated. Pierce ECL
reagents were used to detect HRP conjugated secondary antibody. Blots were
developed using the Chemi-Hi setting on the ChemiDoc™ XRS (BioRad) system

and digital images were obtained using Quantity One software.
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Antibodies

a-FLAG antibody was purchased from Stratagene and used per
manufacturer’s suggestion. a-Tubulin, a-UAP56, a-TAT-SF1, a-NS1, a-Glu Glu
antibodies were purchased from Abeam and used per manufacturer’s

suggestions. Secondary HRP coupled a-Mouse and a-Rabbit were purchased
from Pierce.

GFP Detection
GFP was visualized with a Nikon Eclipse TS100 (Nikon Intensilight C-

HGFI for fluorescence) inverted microscope and images captured with the Nikon
DS-QiMc camera with NS Elements software.

Binding and Oligomerization Assays
Total protein extracts were purified with a-Flag antibody as in co

immunoprecipitation protocol. Purified WT NP and mutant NPs were incubated
with small single stranded DNA (biotin5’/3flu)
AGCAAAAGCAGGGTGACAAAGACATGTAAAAAACACCCTTGTTTCTACT that

is modified with a biotin label. After the incubation period the samples were run

out on an 8% TBE native gel and visualize by western blot using HRP conjugated

streptadivin. Purified WT NP and mutant NPs were allowed to oligomerize for a
short period of time. After the incubation period the samples were run out on an

8% TBE native gel and visualized by western blot using a-Flag antibody.

24

influenza cRNA

Figure 5. Expression of recombinant viral ribonucleoprotein complexes.

Nucleoprotein, polymerase proteins PB1, PB2, and PA are expressed via pcDNA

plasmids, which are transcribed into mRNAs by host RNA polymerase II.
Influenza vRNA templates were expressed via pHH21 plasmids which are
transcribed by host RNA polymerase I. Assembly leads to functional vRNPs in

the nucleus, which both replicate and transcribe the vRNA template.
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CHAPTER THREE
NUCLEOPROTEIN AND POLYMERASE COMPLEX INTERACTION

Introduction

The nucleoprotein (NP) is a component of the functional vRNPs. NP

coats the viral RNA and the RdRP transcribes coated vRNA to viral mRNA and
replicates viral RNA in the nucleus. It has yet to be determined how the influenza

viruses shift from transcription to viral genome replication. NP is involved in the

switch and three models have been proposed to illuminate the mechanism;
stabilization, template modification, and polymerase modification (Klumpp 1997,
Newcomb 2009, Vreede 2004).

The “stabilization” model suggests that newly synthesized NP and

polymerase proteins stabilize nascent cRNA in the nucleus, protecting it from

host cell degradation, and resulting in viral genome replication later in the
infection (Vreede 2004). The “template modification” model proposes that free
NP binds template RNA resulting in structural modifications that leads to the

switch from transcription to replication (Klumpp 1997). The proposed
mechanisms behind the “stabilization” and the “template modification" models

require that NP interact with RNA to get cRNA synthesis. However, blocking the
RNA binding site on NP with ssDNA does not alter its ability to enhance cRNA

synthesis in vitro (Newcomb 2009). The “polymerase modification” model
hypothesizes that the switch from transcription to replication is due to a direct
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interaction between NP and the polymerase .complex. Co-immunoprecipitation
data show that NP that is unable to bind RNA still interacts directly with the RdRP

(Newcomb 2009). This in vitro data supports the “polymerase modification"

model. More conclusive support for the “polymerase modification” model would
be to show correlating results in vivo. Therefore, we set out to identify and
characterize an NP mutant which maintains the ability to bind nucleic acids but is

unable to interact with the viral RdRP.

Amino Acid Modifications to Nucleoprotein
Regions of the NP protein that are highly accessible for interactions with

other molecules were identified using DeepView/Swiss Pdb Viewer to visualize
the resolved NP crystal structure (Ye 2006). To narrow down possible

candidates, regions that are highly conserved across all influenza subtypes (Li
2009, Mena 1999, Shu 1993) were targeted, while residues located within the

RNA binding domain or the oligomerization region were avoided. Based on

these observations two mutants were created (Figure 6, Daniel Smith, Newcomb

Lab).
The first NP mutant was created by modifying amino acid residues Y289A,
R293A, E294A, G308A, and N309G and was named NPbd3. The second NP

mutant was created modifying amino acid residues S467G, E469G, K470C,
A471G, and T472G and was named NPbd5. In order to easily detect mutants

NPbd3 and NPbd5 as well as wild type (WT) NP a FLAG epitope tag was
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engineered at the C-terminus of these proteins. WT-NP-FLAG is as functional as
untagged WT-NP as a recombinant vRNP (Figure 7). The creation arid initial
testing of NPbd3 and NPbd5 was performed by Daniel Smith in the Newcomb

Lab.

NPbd3 and NPbd5 Function

Both of these mutants have been tested multiple times for functionality in
viral gene expression as recombinant vRNPs with various vRNA templates in

293T tissue culture cells. Recombinant vRNP expression in 293T cells requires

the viral polymerase proteins and either NPbd3, NPbd5, WT NP, or vector as a
negative control, and FLAG-NS vRNA as template.

Analysis of activity by Western blot with a-FLAG antibody confirmed
expression of the NP mutant proteins and showed that NPbd3 activity is

significantly reduced compared to WT NP with FLAG-NS vRNA template, while

NPbd5 activity is similar to that ofWT NP (Figure 8).
By comparing GFP expression with different NP mutant proteins and using
GFP-M vRNA template we determined the functionality of each of the NP

mutants. 293T cells transfected with NPbd5 showed similar amounts of cells

expressing GFP when compared to cells transfected with WT NP. This

confirmed that NPbd5 was functional similar to WT NP. NPbd3 had no GFP
expression compared to WT NP; therefore it was non-funotional for GFP-M vRNA
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reporter gene expression (Figure 9). Therefore, NPbd3 is nonfunctional and
NPbd5 is functional compared to WT NP.
Reverse transcription-PCR (RT-PCR) confirmed the protein defect at the

level of viral RNA synthesis (Figure 10). Only background NS1 mRNA is

synthesized in the presence of NPbd3, while spliced NS2 mRNA is detected in
the presence of NPbd5, similar to WT NP. Together these results identify the

NPbd3 mutant as nonfunctional for viral RNA expression.

NPbd3 RNA Binding and Oligomerization

To assay RNA binding and oligomerization, WT-NP-FLAG and NPbd3

were purified from 293T cells using anti-FLAG antibody and subjected to a gel
shift assay with biotin labeled single stranded DNA. Experiments showed NP bd3

binds nucleic acid as WT (Figure 11). This assay was further optimized for WTNP using highly purified NP and resulting in cleaner gel shift analysis under these
optimized conditions (See Chapter Four, Figure 15). Future research will confirm

the initial gel shift (Figure 11) using the optimized conditions for better NP
purification.

NPbd3 Interaction with the Polymerase Complex
To determine if NPbd3 is deficient in interaction with RdRP as intended,

immunopurification was again employed. a-FLAG antibody purification of WT-NP
leads to little co-immunopurification with the viral polymerase, even when cross
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linking reagents are added prior to immunopurification. However, NP-RdRP

interaction can be assessed using a-GluGlu antibody to immunopurify a Glu-Glu
tagged PB1 subunit, as demonstrated in cells expressing recombinant vRNPs
comprised of WT-NP and PB1-GluGlu vRNA (Figure 12). Future research will
express this PB1-GluGlu subunit via a pcDNA plasmid in order to assess NPbd3
interaction.

Summary

NPbd3 characterization thus far indicates the mutant is expressed and maintains
nucleic acid binding, but suggests it is defective for viral RNA synthesis or

processing. The protocols required to complete characterization have been
optimized and will be employed to determine if interaction with the viral RdRP is

disrupted. (See Chapter 5, Discussion and Future Research)
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Figure 6. Three dimensional model of nucleoprotein
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No NP

WT-NP

NP C-term FLAG
UV
Figure 7. Wild type NP-FLAG is as functional as untagged wild
type NP. 293T cells were transfected with recombinant vRNPs

expressing either untagged wild type NP, C-terminal tagged
wild type NP, and vector as a negative control using GFP-M

vRNA as template.

GFP protein was visualized with Nikon

Eclipse TS100 (Nikon Intensilight C-HGFI forfluourescence).
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WTNP

NPbd5 Npbd3

NoNP

pHH21 NS Flag vRNA
1

Figure 8. 293T expression and function
of NPbd3 and NPbd5. 293T cells were
transfected with recombinant vRNPs
containing either WT-NP, NPbd5,

NPbd3, or no NP with FLAG-NS vRNA.
Protein extracts were isolated and
analyzed by Western blot. a-FLAG

antibody was used to detect FLAG
epitope tagged proteins.
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Figure 9. Analysis of NPbd3 and NPbd5
through expression of GFP tagged proteins.

293T cells were transfected by Daniel
Smith with recombinant vRNPs expressing
either WT NP, NPbd5, or NPbd3 with GFP-

M vRNA. Fluorescence microscopy image

showing NPbd5 is functional for GFP-M
vRNA gene expression as WT NP. GFP
protein was visualized with a Nikon Eclipse

TS100 (Nikon Intensilight C-HGFl for
fluorescence).
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Figure 10. Confirmation of NPbd3 and

NPbd5 function at the level of RNA.
293T cells were transfected with
recombinant vRNPs containing either

WT-NP, NPbd5, NPbd3, or no NP with
Flag-NS vRNA. RNA was isolated and

DNase treated prior to analysis via
reverse transcription-PCR.
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Figure 11. NPbd3 binds nucleic acids as wild
type NP. 293T cells were transfected with

either NPbd3, WT-NP, or No NP. Total
protein extracts were collected and NP was
immunopurified with a-FLAG antibody.
Purified NP proteins were incubated with

single stranded Biotin labeled DNA and
separated on a Native gel. Initial Western
blot results performed with Streptadivin-HRP

to detect NPbd3 binds single stranded DNA
as WT-NP.
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immunopurifies with PB1-GluGlu. 293T
cells were transfected with plasmids to
express recombinant vRNPs containing

either WT-NP, or no NP with PB1 GluGlu vRNA. a-GluGlu antibody was used

to immunopurify PB1-GluGlu. Western
Blot with a-FLAG antibody demonstrates

co-immunopurification of WT-NP-FLAG.

HC designates the heavy chain.
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CHAPTER FOUR

N-TERM1NAL NUCLEOPROTEIN INTERACTIONS

Introduction

Among the many proposed interactions with host cell factors, NP has
been suggested to interact with host cell transcription elongation factor Tat-SF1

(Naito 2007) and host cell splicing factor UAP56 (Momose 2001). In both cases,
the host factors were shown to interact with free NP and not with NP that is
associated with viral RNA, suggesting that they function as chaperones for NP
leading to the formation of NP-RNA complexes and thus enhancing viral RNA

synthesis (Momose 2001, Nagata 2008, Naito 2007, Kawaguchi 2011). Tat-SF1

is a general RNA elongation factor (Parada 1999, Zhou 1996) and may also play

a similar role during influenza viral RNA elongation. UAP56 was first identified as
a splicing factor but has also been implicated in mRNA nuclear export by

interacting with the mRNA and other export proteins (Linder 2001, Shen 2009).
Another suggested role for UAP56 has been proper cytoplasmic localization of
exported mRNA. UAP56 interacts with mRNPs in the cytoplasm, causing them

to remodel and localize properly (Linder 2001). It could be possible that during
influenza virus infection host UAP56 could play similar functions with viral mRNA.

Yeast two hybrid and GST pull down analysis show that UAP56 interacts with NP
and the N-terminus 20 amino acids of NP are sufficient for this interaction
(Momose 2001).
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Construction of del20NLS-NP
To examine the role of the NP interactions with host mRNA processing

factors, we targeted the UAP56 interaction and created a plasmid to express an
NP mutant with the first 20 N-terminus amino acids deleted. This region contains

the non-conventional nuclear localization signal (NLS) that is responsible for

proper localization of NP and subsequently the vRNPs to the nucleus (Figure

12A). A conventional NLS from the SV40 T-antigen was added to replace the
non-conventional NLS and allow for proper localization of functional vRNPs to

the nucleus where viral transcription and replication occur (Palese 2007) (Figure

12B). To facilitate the detection of the del20NLS NP mutant, a FLAG epitope
was engineered at the C-terminus of the protein. WT-NP-FLAG is as functional

as untagged WT-NP as a recombinant vRNP (Figure 7).

del20NLS-NP is Expressed in the Nucleus
the Same as Wild Type NP

To confirm del20NLS NP was expressed in the nucleus as WT NP, 293T
cells were transfected with plasmids to express del20NLS NP, WT NP, or no NP

together with GFP-M and PB1-GluGlu vRNA templates as described in Chapter
Two, Materials and Methods. Nuclear and cytoplasmic protein extracts were

isolated and separated by SDS-PAGE. Western analysis with a-FLAG antibody

showed that the del20NLS NP mutant localizes to the nucleus and cytoplasm as
wild type NP (Figure 14). Hsp90 is a cytoplasmic protein, while SP1 and Nxf1
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are nuclear localized proteins. Proper expression of these proteins to either the
cytoplasm or nucleus demonstrates successful cellular fractionation.

de!20NLS-NP Retains Nucleic Acid Binding
as Wild Type NP
To confirm that the del20NLS NP retains its RNA binding pocket and binds

single stranded nucleic acids, 293T were transfected with either de!20NLS NP,

WT NP.orNoNP. Total protein extracts were collected and immunopurified with

a-FLAG antibody. The samples were separated by SDS-PAGE and stained with
Coomassie Blue, demonstrating pure de!20NLS NP and WT NP isolation with no
contaminating proteins (Figure 15A). The purified samples were then incubated

for a short time with single stranded biotin labeled DNA to allow NP to interact

with single stranded DNA. Single stranded DNA was used instead of RNA since
the crystal structure of NP reveals a positively charged binding pocket, able to
interact non-specifically with the negative phosphate backbone of either DNA or

RNA (Ye, 2006) (Figure 6). Further, it has been previously demonstrated that
single stranded DNA blocks NP-RNA binding, supporting that both nucleic acids

interact via the same binding pocket (Newcomb 2009). After the short incubation

period the samples were separated on a native gel. After transfer to a
membrane, western blot analysis was performed with streptadavin-HRP to detect

the labeled DNA. DNA alone migrated quickly through the gel while DNA bound

to NP remained near the top of the gel, confirming the NP-DNA interaction with
both WT NP and del20NLS NP (Figure 15B). Since del20NLS NP lacks the N-
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terminus 20 amino acids, oligomers of del20NLS NP will be slightly smaller and
as a result migrate through the native gel slightly faster than WT NP.

Activity of del20NLS-NP with NS
and M vRNA Templates
To test the function of del20NLS NP for viral mRNA synthesis, processing,

and export, we expressed the del20NLS NP mutant and RdRP with NS and M
vRNA templates; NS vRNA, M vRNA, FLAG-NS vRNA, FLAG-M vRNA, GFP-NS,

or GFP-M vRNA. The NS and M gene segments were investigated first because

they produce spliced products and were speculated to be more dependent on NP

interaction with host splicing factor UAP56. GFP adds significant size to the
vRNA template while the size of the FLAG epitope is probably negligible at 21

nucleotides. Total protein products and total RNA was isolated and collected.

FLAG tagged and untagged protein products were separated by SDS-

PAGE and their expression was analyzed by western blot using a-FLAG antibody
to detect FLAG tagged proteins, a-Udorn antibody to detect M1 protein, and a-

NS1 antibody to detect NS1 protein. FLAG-NS and untagged NS genes were
expressed normally with del20NLS NP and with WT NP. FLAG-M and untagged

M gene expression with de!20NLS NP was defective compared to WT NP. Gene
expression of the FLAG-M and untagged M genes was not completely defective

since some spliced M2 and intron containing M1 products can be observed
(Figure 16). Together these results indicate that there is no defect in splicing.
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GFP protein products were visualized by fluorescence microscopy in vivo

(Figure 17). GFP-M gene expression is completely obliterated with del20NLS NP

compared to WT NP, while GFP-NS expression is significantly reduced. We
observed a significant reduction in FLAG-M gene expression while GFP-M

expression is completely shut down in the presence of de!20NLS NP. By
comparison, FLAG-NS gene expression was seemingly unaffected, but GFP-NS

gene expression is considerably reduced in the presence of del20NLS NP. M

and NS are similar in size, where M is 137 nucleotides longer than NS. Together
this data suggests that as the size of the gene template increases, gene

expression is worsened. Our results are consistent with previous reports that the

N-terminus of NP interaction with host UAP56 is involved in coating of nascent
viral RNA products (Momose 2001, Kawaguchi 2011). In addition, because M
and NS are similar in size it appeared that the M gene was more dependent on
the function of the N-terminus of NP than the NS gene.

Total RNA was analyzed by reverse transcription-polymerase chain

reaction (RT-PCR) to determine whether the observed protein expression defect
is due to changes in RNA levels (Figure 18). The reverse transcription (RT) was

performed with oligo dT to detect full length mRNA transcripts. The PCR

reaction was performed with primers specific to the genes being analyzed.
Results show the gene expression defect is due to a defect in viral RNA

synthesis which is abrogated as the vRNA template length is increased. This is
demonstrated by expression of untagged or FLAG-NS2 mRNA but not GFP-NS2
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mRNA in the presence of del20NLS-NP. Therefore, we speculate the defect is

during RNA elongation or processivity; however, we cannot rule out inefficient
vRNP formation, which could also be influenced by vRNA template length.

del20NLS-NP is Defective for both Early
and Late Viral Genes
Influenza genes are either ‘early’ (PA, PB1, PB2, NP and NS1) or ‘late’

(segments HA, NA, M1, M2 and NS2), based on the temporal expression
patterns of their protein products (Hatada 1989, Inglis 1979, Lamb 1978, Skehel

1972). The M gene segment is expressed late during viral infection and the NS

gene segment is expressed early during viral infection. Since del20NLS NP is
defective for M but not NS gene expression, the expression of PA and PB1,
which are early expressed genes, and HA, a late expressed gene, was examined

to determine if the N-terminus of NP is involved in temporal expression of viral
gene segments.
293T cells were transfected with plasmids to express recombinant vRNPs

comprised of del20NLS NP, WT NP, or no NP, and FLAG-PA or PB1-GluGlu

vRNA templates. Viral gene expression results in FLAG epitope tagged PA or
GluGlu epitope tagged PB1 proteins. The epitope tag facilitates distinguishing

PA and PB1 proteins expressed via activity of the recombinant vRNPs from
untagged PA and PB1 proteins expressed via transfections. Total protein

extracts were isolated, separated by SDS-PAGE, and probed by Western
analysis with either a-FLAG antibody to detect PA protein products or a-GluGlu
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antibody to detect PB1 protein products. Expression of both PA and PB1
proteins was severely inhibited (Figure 19A and 19B).
To analyze HA gene expression 293T cells were transfected with

recombinant vRNPs expressing del20NLS NP, WT NP, or No NP and Ud-HA

vRNA. Probing with a-HA antibody to detect HA protein products showed that

HA expression was also severely inhibited. Protein results were confirmed at the
level of RNA by reverse transcription with oligo dT and PCR with gene specific
primers (Figure 20A and 20B). Together, these results show that del20NLS NP

is defective with both early and late expressed genes.

del20NLS-NP is Defective for Short
Viral Gene Expression
Since FLAG-NS and untagged NS gene expression was seemingly
unaffected, we speculated that template length might account for the defect

observed with the del20NLS NP mutant. NS is 137 nucleotides shorter than M.
To test if template length plays a significant role in the viral RNA expression

defect observed in the presence of de!20NLS NP, a truncated FLAG-M (FLAG-

M2) that encodes for only the FLAG-M2 gene and is a smaller RNA segment
than the NS segment, was expressed in the recombinant vRNPs. FLAG-M2

gene expression was defective with the del20NLS NP (Figure 21) similar to full
length M gene expression (Figure 16). This suggests that template length does
not account for the defect observed with the de!20NLS NP mutant.
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NS1 Protein Rescues the RNA Expression Defect
Observed with de!20NLS-NP

Since our results indicated that all viral RNA expression was inhibited in
the presence of de!20NLS-NP except NS, we hypothesized that either the NS1A
or NS2 protein product rescued the RNA expression defect observed in the

presence of del20NLS-NP. The del20NLS-NP defect is not completely deficient
in viral gene expression but rather severely inhibited, resulting in barely

detectable protein and RNA expressed from the M, PA, and HA vRNA templates

(Figures 16 and 19A, 20A). Therefore, we reasoned that minimal expression of
NS proteins led to rescue of the RNA expression defect, resulting in normal

levels of NS1A and NS2 proteins and RNA (Figure 16).
To test if either NS1A or NS2 rescues the RNA expression defect, we

transfected 293T cells with either pcDNA NS, which expresses both NS1A or

NS2, or pcDNA NS1ss, which expresses a splice site mutant resulting in the

expression of only NS1A. Comparing the M protein expression with or without
the addition of NS proteins we find that NS1A protein rescues the gene

expression defect of the M gene observed with the del20NLS NP mutant (Figure
22). NS1A also rescue gene expression defect seen with longer templates, such
as the early expressed PA gene (Figure 23). Therefore, minimal expression of

NS1A resulted in the rescue of the observed RNA expression defect.
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Summary
Characterization of del20NLS-NP suggests a functional interaction between

NS1A and NP and a role for NS1A in viral RNA expression. NS1A interacts with
vRNPs during infection (Marion 1997, Kuo 2009). This interaction was recently
attributed to contacts with RNA and NP, rather than the viral RdRP (Robb 2011).

In addition, a number of NS 1A mutant viruses exhibit alterations in viral RNA
synthesis (Falcon 2004, Min 2007), suggesting that NS1A may play an active

role in regulation of viral RNA expression. My results compliment published

research and make a significant contribution to further understanding
mechanisms and regulation of influenza viral RNA expression.
Further characterization of de!20NLS-NP defect and rescue by NS1A will

elucidate the mechanism by which NS1A rescues this NP mutant. The defect

and rescue are likely either at the level of vRNP formation or RNA polymerization
processivity. To address vRNP formation we will use immunopurification of

vRNPs; this will be performed as described for WT-NP in Chapter 2 but in the
presence and absence of NS1A and defined NS1A mutants. To address RNA

processivity, RNA will be analyzed for the presence of abortive transcripts.

These experiments are being carried out in the laboratory and should reveal at
which step del20NLS NP is defective and exactly how NS1A rescues this defect

and exerts an effect on viral RNA expression.
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Figure 13. Deletion of N-terminus 20 amino acids of nucleoprotein. A. Regions
of NP that have been reported to interact with host cell factors. B. Schematic of

del20NLS-NP mutant. del20NLS-NP mutant construction by Fady Boutros.
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Figure 14. Expression of del20NLS-NP in the nucleus

and the cytoplasm as wild type NP. 293T cells were
transfected with recombinant vRNPs containing either
del20NLS NP, WT-NP, or no NP together with GFP-M

and PB1-GluGlu vRNA. Nuclear and cytoplasmic

extracts were isolated and analyzed by western
analysis. a-FLAG antibody was used to detect FLAG

epitope tagged proteins. Hsp90 is a cytoplasmic
protein. a-Hsp90 was used to detect Hsp90 protein.
Sp1 is a nuclear protein. a-Sp1 was used to detect Sp1

protein. Nxf1 is a nuclear protein. a-Nxf1 was used to

detect Nxf1 protein.
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Figure 15. Nucleoprotein purification and nucleic acid binding. 293T cells were

transfected with either del20NLS NP, WT NP, or No NP. Total protein extracts

were collected and NP was immunopurified with a-FLAG antibody. A. Purified
NP proteins were separated by SDS-PAGE and stained with Coomassie Blue.

B. Purified NP proteins were incubated with single stranded Biotin labeled DNA
and separated on a Native gel. Western analysis was performed with a-Biotin to
detect NP binding to the single stranded DNA.
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Figure 16. Western blot analysis of tagged and untagged NS and M genes.

293T cells were transfected with recombinant vRNPs expressing either

de!20NLS NP, WT NP, or no NP with either FLAG-NS vRNA, FLAG-M vRNA,

untagged NS vRNA, or untagged M vRNA reporter genes. Total protein was

isolated and analyzed by western blot. A) a-FLAG antibody was used to detect
FLAG epitope tagged proteins. Tubulin was used as a loading control. B) aNS1 antibody was used to detect NS1 protein and a-Udorn antibody was used to

detect M1 protein. a-Tubulin antibody was used to detect tubulin.

50

A.

GFP-M vRNA

GFP-NS vRNA
Figure 17. Expression of M and NS genes tagged with GFP. 293T cells were
transfected with recombinant vRNPs expressing either del20NLS NP, WT NP, or

no NP with either A) GFP-NS vRNA or B) GFP-M vRNA reporter genes. GFP
protein was visualized with a Nikon Eclipse TS100 (Nikon Intensilight C-HGFI for
fluorescence).
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Figure 18. Reverse transcription polymerase chain reaction analysis to
confirm defect in the presence of del20NLS-NP is at the level of RNA
expression. 293T cells were transfected with recombinant vRNPs
containing either WT-NP, del20NLS-NP, or no NP with either A) FLAG-M

vRNA or FLAG-NS vRNA or B) GFP-M or GFP-NS vRNA as template.
Total RNA was isolated and DNase treated prior to analysis via reverse
transcription-PCR. PCR product was analyzed, over sequential cycles. No

reverse transcription (RT-) serves as negative control.
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Figure 19. Expression of PA and PB1 vRNA templates with de!20NLS-NP. 293T
cells were transfected with recombinant vRNPs expressing either del20NLS NP,

WT NP, or No NP with either Flag-PA or PB1-GluGlu vRNA. Total protein was
isolated and analyzed by Western blot. Total RNA was isolated and DNase

treated prior to analysis by RT-PCR. No reverse transcription (RT-) serves as a

negative control. A. a-FLAG antibody was used to detect FLAG epitope tagged

proteins. B. a-GluGlu was used to detect GluGlu epitope tagged proteins.
Tubulin was used as a loading control.
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Figure 20. Expression of HA vRNA with de!20NLS-NP. 293T cells were
transfected with recombinant vRNPs expressing either del20NLS NP, WT NP, or
No NP with Ud-HA vRNA. A. Total protein was isolated and analyzed by

Western blot. a-HA antibody was used to detect HA protein products. Tubulin
was used as a loading control. B. Total RNA was isolated and DNase treated

prior to analysis by RT-PCR. No reverse transcription (RT-) serves as a negative
control.
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Figure 21. Short M gene expression was
defective with de!20NLS-NP. 293T cells were
transfected with recombinant vRNPs expressing

either de!20NLS NP, WT NP, or no NP with
short FLAG-M vRNA reporter gene. Total

protein was isolated and analyzed by Western
blot. a-FLAG antibody was used to detect

FLAG epitope tagged proteins.
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template. 293T cells were transfected with
recombinant vRNPs expressing either del20NLS NP,

WT NP, or No NP and with either NS or NS1 with
FLAG-M vRNA. Total protein was isolated and
analyzed by Western blot. a-FLAG antibody was

used to detect FLAG epitope tagged protein products.

Tubulin was used as a loading control.
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Figure 23. NS1 rescues expression defect with

PA template. 293T cells were transfected with
recombinant vRNPs expressing either del20NLS

NP, WT NP, or No NP and with either NS or NS1

with FLAG-PA vRNA. Total protein was isolated
and analyzed by Western blot. a-FLAG antibody
was used to detect FLAG epitope tagged protein

products.
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CHAPTER FIVE
DISCUSSION AND FUTURE RESEARCH

Introduction
Every year influenza virus infections pose a threat to human health (World
Health Organization2009, Cox 2000) and as a consequence adds strain to the

global economy (Lagace 2010). This makes it critical to find an effective method
to prevent influenza infections or create reliable antiviral medications that can

circumvent antigenic variation that is intrinsic to the influenza virus (Palese 2007,
Cox 2000, Johansson 2007, Blaser 2007). Current approaches are ineffective

against emergent pandemic threats (Cox 2000, Johansson 2007). NP is a
multifunctional protein that could be a target for novel antiviral medications due to
limited antigenic variation (Shu 1993, Li 2009, Mena 1999) and its involvement in

many aspects of the virus life cycle (Portela 2002).

Nucleoprotein and Polymerase
Complex Interaction

NP is involved in the switch from viral mRNA transcription to viral genome

replication (Beaton 1986, Biswas 1998, Klumpp 1997, Newcomb 2009, Vreede
2004). In vitro results support the “polymerase modification” model which
advocates that NP interacts directly with the polymerase complex leading to

enhanced unprimed RNA synthesis or replication, and culminating in the switch
from transcription to replication (Newcomb 2009). Other models include
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‘stabilization’ and ‘template modification’, both requiring the RNA binding activity

of NP (Klumpp 1997, Vreede 2004). To differentiate between these three models,
mutant NP proteins were designed to maintain overall NP structure and RNA
binding pocket, but to be deficient in interaction with the viral RdRP. Two

mutants, NPbd3 and NPbd5, were created by selecting regions of NP that are
highly conserved across all influenza subtypes and using the crystal structure to

identify highly accessible amino acids that might be involved in interactions with

other proteins, specifically targeting NP regions previously implicated in RdRP
interaction (Biswas 1996). The goal was to identify regions of NP that interact

with the RdRP and disrupt this interaction. This research showed NPbd5
remained functional in recombinant vRNP assays, but NPbd3 was shown to be
nonfunctional for viral RNA synthesis.
The mutations to NPbd3 were made on the body domain of NP (Figure 6).

RNA binding and oligomerization are important properties for NP. Modifications

to these domains will result in a nonfunctional protein. We have shown that

NPbd3 is able to interact with nucleic acids similar WT NP, suggesting that the
observed defect is not a consequence of failed RNA interaction (Figure 11). The
gel shift assay showed that NPbd3 looks.to migrate the same as WT NP and

suggest that it also retains the ability to oligomerize. To confirm that NPbd3 self

associates as WT NP, migration on a native gel of NPR416A, a NP mutant which
lacks the ability to oligomerize (Ye 2006), will be compared to NPbd3 and WT NP

on a native gel. We expect that NPbd3 is able to oligomerize.
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Co-immunopurification experiments to determine if NPbd3 is able to

interact with the RdRP have resulted in little success. Recently we have been
able to investigate the WT NP-RdRP interaction using a a-GluGlu antibody to
immunopurify a GluGlu tagged PB1 subunit. Expression of PB1-GluGlu has

been via functional vRNP containing PB1-GluGlu vRNA. Continued work will

express the PB1-GluGlu subunit by way of a pcDNA and not vRNA. Therefore,
analysis for interaction between non-functional NPs, such as NPbd3, and the

RdRP will be possible.
If NPbd3 is found to be defective for interaction with the viral RdRP, future
work will be to perform further mutational analysis to target the five mutated

modified NPbd3 amino acids individually to reveal the specific interaction site and

amino acids essential for interaction. Defining this essential NP surface would
reveal a potential antiviral target to design peptide or other small molecule based

inhibitors to disrupt this interaction.

Antigenic variation in influenza is an obstacle for the development of a
long lasting vaccination against infection. Drug resistant influenza viruses have

also resulted as a consequence of antigenic variation. Vaccination and antiviral
drug development targets influenza envelope proteins which rapidly evolve as a

result of the lack of fidelity by the virus replication machinery. Whether NPbd3
binds the RdRP or not, this research demonstrates that NPbd3 is mutated at
amino acid residues essential for viral RNA synthesis. NPbd3 maintains nucleic

acid bind and oligomerization, indicating overall protein structure is probably
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intact. Therefore, this research reveals an essential NP domain which may
provide an effective antiviral target due to NPs highly conserved genome

segment.

Nucleoprotein N-Terminal Interactions
NP is a multifunctional protein with roles at different times during the

influenza virus life cycle. The major function for NP is to bind the viral RNA
segments and together with the RdRP form a functional vRNP, which is
responsible for viral transcription and genome replication in the nucleus. NP has

also been demonstrated to interact with host splicing factor UAP56 and

transcription elongation factor TatSFI. Both of these interactions have been
implied to facilitate the binding of free NP with vRNA and cRNA resulting in
increased viral RNA replication (Nagata 2008, Momose 2001, Kawaguchi 2011).
In this study we set out to investigate the interactions between NP and splicing
factor UAP56.

Influenza RNA synthesis and processing occurs in the nucleus. The N-

terminus of NP contains a nonconventional nuclear localization signal (NLS)
which is responsible for proper localization of vRNPs to the nucleus (Cros 2005,
Wang 1997). This NLS has been mapped to amino acids 1 to 13 (Wang 1997).

The N-terminal 20 amino acids of NP have been reputed to be sufficient for
binding UAP56 (Momose 2001). To investigate the role of the NP N-terminus, a

mutant was engineered with a conventional NLS from the SV40 T-antigen in
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place of the N-terminal 20 amino acids. We found this mutant localized to the
nucleus, where viral RNA synthesis occurs (Figure 12), and also retains the

ability to bind nucleic acids as WT-NP (Figure 13B).
With the exception of the NS gene template, the de!20NLS NP mutant was
defective for viral RNA expression with every viral template tested, including both

early and late viral genes (Figures 14, 15, 17, 18, and 19A). While length

appears to worsen the RNA expression defect, both long and short viral
templates were defective for RNA expression (Figures 17, 18, and 19A) in the
presence of del20NLS NP. Recently it has been suggested that UAP56

mediates the association of free NP with nascent RNA resulting in its stabilization
and subsequently facilitating RdRP processivity leading to increased viral RNA

expression (Kawaguchi 2011), lending support to the “stabilization model”

(Vreede 2004). The RNA expression defect caused by the del20NLS NP could
be attributed to the NP N-terminus modification, leading to the obstruction of the

NP-UAP56 interaction, resulting in inefficient loading of free NP to nascent viral
RNA. In this context, our results agree with in vitro data by Momose et al. (2001)

and Kawaguchi et al. (2011). However, we cannot confirm that the de!20NLS NP

defect is exclusively due to the disrupted interaction between NP and host cell

factors because we have been unable to demonstrate the protein-protein

interaction between WT NP and UAP56. Other reports have demonstrated that
siRNA inhibition of UAP56 does not have a significant effect on viral RNA
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synthesis (Read 2010). It is necessary to work out a better protocol to confirm

the purported NP-UAP56 interaction occurs.

The NS segment was the only template to result in RNA expression when
co-expressed with del20NLS NP. We hypothesized that this normal RNA

expression could be a consequence of minimal initial expression of NS mRNA
from the NS vRNA template that produces NS protein products, NS1A and NS2,

from intron containing NS1A or spliced NS2 mRNAs, respectively. This initial

minimal NS protein expression then resulted in rescue of the RNA expression

defect, leading to more robust NS mRNA expression and no observable defect in
NS protein expression. Indeed, we found that expression of NS1A alone rescued

the del20NLS-NP RNA expression defect (Figure 20).
NS1A is a multifunctional protein that can network with a number of host

and viral proteins. The principal action of NS 1A is to antagonize the host
interferon (IFN) antiviral response (Hale 2008). NS1A interacts with CPSF30, a

host cell factor that is required for 3’ polyadenylation of all host cell mRNAs. This
results in the inhibition of host cell mRNA synthesis, including IFN mRNAs (Twu

2006). Viral RdRP polyadenylates the 3’ end of viral mRNAs (Li 1994, Zeng
1999) and does not require the activity of CPSF30. By preventing host mRNA
processing, NS1A is able to inhibit the production of IFN and block the antiviral
response without affecting viral mRNA synthesis. An alternate manner in which

influenza virus can counter the IFN response is through interaction with protein

kinase R (PKR). Mutations to the C-terminus of NS1A have revealed an N-
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terminal binding site for PKR which leads to inhibition of the PKR pathway. The

ability of NS1A to inhibit the host IFN antiviral response could possibly result in
the recovery of RNA expression with del20NLS NP. For example, NS1A

prevents activation of host RNase L, which could degrade any viral RNA
synthesized (Min 2006). It seems likely that this is not the mechanism for rescue
as addition of NS 1A to WT NP recombinant vRNPs does not increase viral RNA

expression, which would be expected if NS1 indirectly inhibited RNase L
activation. We recently obtained data demonstrating that a NS1A RNA binding

deficient mutant (NS1R38A) also rescues the del20NLS-NP defect (Figure 24).
These data suggest that rescue is not due to NS1A RNA binding and thus not
due to an indirect inhibition of RNase L. To further rule out an indirect rescue

due to IFN antagonistic properties, the NS1 protein from influenza B (NS1B) will
be tested for rescue of the defect. NS1B does have IFN antagonistic properties,

but does not use the same mechanisms as NS1A. For example, NS1B does not

interact with CPSF30 (Wang 1996). We expect NS1B will not be able to rescue
the de!20NLS-NP mutant.

In addition to its role as an IFN antagonist, NS1A also interacts with the

vRNP (Marion 1997, Kuo 2009) and this interaction is attributed to an interface
with NP and viral RNA, but not the polymerase complex (Robb 2011). Since the
NS1A R38A RNA binding deficient mutant retains the ability to rescue (Figure

23), it seems likely that the rescue observed is not due to NS1A-RNA interaction,

but rather due to a true functional interaction between NP and NS1A. Future
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work will aim to elucidate the reason for the de!20NLS NP defect and the

mechanism by which NS1A rescues. Two working hypotheses are that the

defect is either at the level of vRNP formation or RNA elongation. To examine
RNA elongation, total RNA extracts will be analyzed to detect abortive transcripts
in the presence and absence of NS1A. This will involve using 3’ gene specific

primers that target the first 150 nucleotides or less during the reverse
transcription step, along with suitable gene specific primers during the PCR step.
To examine vRNP formation, co-immunopurification of a tagged polymerase
subunit will be employed to detect NP-RdRP interaction and compare this to

del20NLS-NP-RdRP interaction both in the absence and presence of NS1 A.
Together these additional experiments should elucidate the reason why
del20NLS-NP is defective for RNA expression and the mechanism for rescue of

RNA expression in the presence of NS1A.
Lastly, it is possible that our observed results are a consequence of NS1A

interaction with host CPSF30. This interaction not only inhibits host 3’
polyadenylation to antagonize IFN, but is also reported to be important in
stabilization of a macromolecular complex which includes the vRNP (Kuo 2009).

The NS1 A-CPSF30-vRNP complex formation requires the cognate PA and NP,
components of the vRNP, for stabilization. The result is a macromolecular

complex that includes NS1A, vRNP, CPSF30, in addition to other host factors
(Kuo, 2009). While this rescue mechanism might be due to initial defect in RNA

elongation, formation of the NS1-CPSF30-vRNP macromolecular complex may
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stabilize vRNP formation as well. Therefore, to test this possibility directly, NS1A
M186A, a CPSF30 interaction deficient NS1A protein (Twu 2006) will be tested

for rescue. If interaction with CPSF30 and formation of the macromolecular

complex is required for rescue, we expect to see no rescue with NS1 M186A.

However, if formation of the macromolecular complex is not required, NS1
M186A should maintain the ability to rescue the defect.

This research is significant because it supports a functional interplay
between NP and NS1A and may reveal biological relevance to the reported

physical interaction (Robb 2011). This data also suggests a role for NS1A in viral

RNA expression, and continued characterization of the del20NLS NP defect and
rescue by NS 1A may help explain why some NS1A mutants have alterations in

viral RNA expression. Understanding this likely functional interaction between

NP and NS1 could illuminate a novel antiviral target

Conclusion

Influenza virus infection is a serious threat to human health, specifically
the looming threat of an emergent highly virulent virus in the human population.

To combat this threat requires a better understanding of the mechanisms
employed by the influenza virus for RNA expression. Understanding how the

virus transitions between each step in its life cycle may illuminate exploitable
points in the viral life cycle that can be targeted to combat this pathogen. A

detailed understanding of the manner in which nucleoprotein interacts with other
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viral proteins, such as NS1A and the RdRP, and with host factors, such as
UAP56, can reveal promising antiviral targets. While the antigenic variability of

influenza adds difficulty to the creation of a long lasting vaccine to avoid virus

infection, investigating viral proteins with stable genetics as potential antiviral
targets could result in a reasonable remedy for seasonal flu infections and

effective treatment during times severe epidemics or pandemics. The influenza

nucleoprotein offers to be a promising candidate for such an antiviral target.
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Figure 24. RNA binding mutant, NS1R38A also rescues the

del20NLS-NP defect. 293T cells were transfected with
recombinant vRNPs expressing either del20NLS NP, WT NP,

or No NP and with either NS or NS1 with FLAG-PA vRNA.
Total protein was isolated and analyzed by Western blot, a-

FLAG antibody was used to detect FLAG epitope tagged
protein products.
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